Table 3:
Univariate and multivariate cox proportional hazard regression analysis for overall survival€
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Hazard ratios (95% CI) |
P-value | Hazard ratios (95% CI) | P-value | |
| Age at diagnosis | 1.05 (1.04 – 1.05) | <0.001 | 1.04 (1.03 – 1.04) | <0.001 |
| Race: | ||||
| White | 1 | 1 | ||
| Black | 1.19 (1.06 – 1.35) | 0.004 | 1.22 (1.07 – 1.38) | 0.003 |
| Other | 0.64 (0.47 – 0.88) | 0.006 | 0.73 (0.53 – 1.00) | 0.051 |
| Unknown | 0.82 (0.55 – 1.22) | 0.331 | 0.84 (0.57 – 1.25) | 0.391 |
| Insurance status: | ||||
| Not insured | 1 | 1 | ||
| Private insurance | 0.62 (0.46 – 0.82) | 0.001 | 0.75 (0.57 – 1.00) | 0.052 |
| Government insurance | 1.57 (1.19 – 2.08) | 0.002 | 0.95 (0.71 – 1.26) | 0.714 |
| Unknown | 1.15 (0.76 – 1.74) | 0.504 | 1.11 (0.74 – 1.69) | 0.609 |
| Median household income in area of residence: | ||||
| < $ 38,000 | 1 | 1 | ||
| $ 38,000 – $ 62.999 | 0.80 (0.72 – 0.90) | <0.001 | 0.89 (0.79 – 1.01) | 0.063 |
| $ 63,000+ | 0.63 (0.56 – 0.71) | <0.001 | 0.78 (0.67 – 0.91) | 0.002 |
| Unknown | 2.32 (1.69 – 3.18) | <0.001 | 1.36 (0.36 – 5.15) | 0.650 |
| Adults without high school degree in area of residence: | ||||
| > 21% | 1 | 1 | ||
| 7 – 20.99% | 0.93 (0.83 – 1.04) | 0.212 | 1.01 (0.89 – 1.16) | 0.810 |
| < 7% | 0.67 (0.58 – 0.76) | <0.001 | 0.86 (0.72 – 1.01) | 0.070 |
| Unknown | 2.61 (1.88 – 3.62) | <0.001 | 1.28 (0.32 – 5.02) | 0.726 |
| County of residence: | ||||
| Metro counties | 1 | 1 | ||
| Urban counties | 1.17 (1.03 – 1.32) | 0.013 | 1.08 (0.95 – 1.22) | 0.253 |
| Rural counties | 1.27 (0.94 – 1.72) | 0.125 | 1.23 (0.90 – 1.67) | 0.191 |
| Unknown | 1.57 (1.28 – 1.92) | <0.001 | 1.23 (0.96 – 1.56) | 0.094 |
| Co-morbidity Index (Charlson/Deyo score): | ||||
| 0 – 1 | 1 | 1 | ||
| 2 – 3 | 3.26 (2.84 – 3.74) | <0.001 | 2.22 (1.93 – 2.55) | <0.001 |
| Histology: | ||||
| Ductal | 1 | 1 | ||
| Lobular | 0.84 (0.67 – 1.06) | 0.150 | 0.93 (0.73 – 1.18) | 0.528 |
| Mixed ductal and lobular | 0.72 (0.55 – 0.95) | 0.018 | 0.94 (0.72 – 1.23) | 0.659 |
| Grade: | ||||
| Well differentiated | 1 | 1 | ||
| Moderately differentiated | 1.52 (1.31 – 1.75) | <0.001 | 1.28 (1.10 – 1.49) | 0.001 |
| Poorly differentiated/Undifferentiated | 2.11 (1.82 – 2.44) | <0.001 | 1.68 (1.44 – 1.95) | <0.001 |
| Unknown | 1.18 (0.92 – 1.52) | <0.001 | 1.07 (0.83 – 1.38) | 0.614 |
| Overall TNM Stage: | ||||
| Stage I | 1 | 1 | ||
| Stage II | 1.79 (1.61 – 1.98) | <0.001 | 1.85 (1.66 – 2.06) | <0.001 |
| Stage III | 3.29 (2.95 – 3.67) | <0.001 | 3.92 (3.44 – 4.46) | <0.001 |
| Estrogen receptor status: | ||||
| Negative | 1 | 1 | ||
| Positive | 1.03 (0.88 – 1.21) | 0.725 | 1.01 (0.83 – 1.23) | 0.921 |
| Unknown | 1.24 (0.98 – 1.56) | 0.070 | 1.46 (0.74 – 2.86) | 0.273 |
| Progesterone receptor status: | ||||
| Negative | 1 | 1 | ||
| Positive | 0.87 (0.79 – 0.97) | 0.012 | 0.82 (0.72 – 0.93) | 0.002 |
| Unknown | 1.04 (0.86 – 1.26) | 0.705 | 0.59 (0.31 – 1.12) | 0.106 |
| Type of surgery: | ||||
| Breast conserving surgery | 1 | 1 | ||
| Total mastectomy | 1.85 (1.66 – 2.07) | <0.001 | 1.16 (1.02 – 1.31) | 0.020 |
| Radiation: | ||||
| No radiation | 1 | 1 | ||
| Received radiation | 0.77 (0.71 – 0.84) | <0.001 | 0.82 (0.74 – 0.90) | <0.001 |
| Unknown | 0.62 (0.44 – 0.89) | 0.008 | 0.77 (0.53 – 1.13) | 0.184 |
| Chemotherapy: | ||||
| Chemotherapy not administered | 1 | 1 | ||
| Chemotherapy administered | 0.67 (0.62 – 0.73) | <0.001 | 0.67 (0.60 – 0.74) | <0.001 |
| Unknown | 0.80 (0.65 – 0.98) | 0.030 | 0.92 (0.72 – 1.16) | 0.480 |
| Hormone therapy: | ||||
| Hormone therapy not given | 1 | 1 | ||
| Hormone therapy given | 0.69 (0.63 – 0.75) | <0.001 | 0.74 (0.68 – 0.81) | <0.001 |
| Unknown | 0.67 (0.57 – 0.80) | <0.001 | 0.70 (0.58 – 0.84) | <0.001 |
€
: Analysis restricted to patients who underwent surgery (N=10327);